Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06962956 · ClinicalTrials.gov registry record · Phase 1
Evaluating Gingivitis and Systemic Biomarkers
A Phase 1 study of Gingivitis, sponsored by Procter and Gamble.
- Active
- Registry status
- Phase 1
- Development phase
- 135
- Enrollment target
- 1
- Study location
NCT06962956: Active Phase 1 study of Gingivitis, sponsored by Procter and Gamble.
NCT06962956 is a Phase 1 study of Gingivitis that is active but no longer recruiting, run by Procter and Gamble. The registered enrollment target is 135 participants, below the 231-participant average among 25 other Gingivitis trials with a reported enrollment target (42% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06962956, a Phase 1 study of Gingivitis, is active but no longer recruiting, sponsored by Procter and Gamble.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 135 participants
- Enrollment target
- 1
- Study location
Study Summary
This exploratory study will consist of two parts: Phase 1 (sample collection/screening) and Phase 2 (sample collection/product efficacy testing). The purpose of Phase 1 is to understand the association of gingivitis to systemic biomarkers and to screen subjects for Phase 2. The purpose of Phase 2 is to assess the causal effect of oral hygiene intervention on gingivitis and systemic biomarkers.
Primary Outcome
Total number of bleeding sites
Conditions Studied
Interventions
- DRUG 0.76% Sodium Monofluorophosphate Dentifrice
- DRUG 0.454% Stannous Fluoride Dentifrice
Study Locations (1)
Indiana
- Salus Research - Fort Wayne
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 135 participants |
| Start Date | 2025-04-30 |
| Est. Completion | 2025-10-31 |
| Phase | Phase 1 |
What the registry record for NCT06962956 still lists
NCT06962956 is an interventional study that assigns participants to a tested intervention. The registered 135 participants enrollment target is mid-sized for trials with a published cap, below the 231-participant average among 25 other Gingivitis trials with a reported enrollment target (42% lower).
The record links to 1 condition, with Gingivitis appearing as the primary indexed condition, and to 2 interventions - of which 0.76% Sodium Monofluorophosphate Dentifrice is the first listed.
NCT06962956 reports a single indexed study location in Indiana.
Frequently Asked Questions
What is clinical trial NCT06962956 about?
NCT06962956 is a clinical study titled "Evaluating Gingivitis and Systemic Biomarkers". This exploratory study will consist of two parts: Phase 1 (sample collection/screening) and Phase 2 (sample collection/product efficacy testing). The purpose of Phase 1 is to understand the association of gingivitis to systemic biomarkers and to screen subjects for Phase 2. The purpose of Phase 2 is...
What is the current status of trial NCT06962956?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 135 participants. The study started on 2025-04-30. Estimated completion is 2025-10-31.
What conditions does trial NCT06962956 study?
This clinical trial studies the following conditions: Gingivitis.
What interventions are being tested in trial NCT06962956?
The interventions under investigation include: 0.76% Sodium Monofluorophosphate Dentifrice (DRUG), 0.454% Stannous Fluoride Dentifrice (DRUG).
Who is sponsoring clinical trial NCT06962956?
This trial is sponsored by Procter and Gamble, which has 70 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06962956 being conducted?
This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gingivitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06962956's enrollment target sits among peer trials
135 11th of 25 higher than 15 of 25 other Gingivitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Gingivitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Six Week Study of Experimental Mouth Rinses: Effect on Gingivitis and Plaque
COMPLETED · Phase 1
-
Imaging-based Assessment of Oral Biofilm and Gingival Health
RECRUITING · NA
-
Extending Dental Care to Nursing Home Residents to Reduce Mouth Infections and Incidence of Pneumonia and Improve Diabetic Glucose Control
RECRUITING · NA
-
A Clinical Study to Evaluate the Effectiveness of an Experimental Toothpaste in Improving Gum Health and Reducing Plaque Accumulation
RECRUITING · NA
-
Effectiveness of Dual Light Electric Toothbrush vs. Manual Toothbrush in Orthodontic Patients Undergoing Oral Surgery
RECRUITING · NA
-
Variation in Gingival Inflammatory Responses
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00870129 · 135 participants · NA
Magnetic Resonance (MR) Imaging to Determine High Risk Areas in Patients With Malignant Gliomas and to Design Potential Radiation Plans and to Examine Metabolite Changes in Gliomas and Other Solid Tumors
- NCT03666000 · 135 participants · Phase 1
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
- NCT04891510 · 135 participants · NA
A Comparative Analysis of REVOLVE, LipoGrafter, and Viality in Autologous Fat Grafting During Breast Surgery
- NCT05121051 · 135 participants · Phase 2
Testing the Effect of the Broccoli Seed and Sprout Extract, Avmacol ES, on the Cancer Causing Substances of Tobacco in Heavy Smokers
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI